AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Consensus Price Target of $37.50

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $37.50.

AGMB has been the topic of several recent analyst reports. Johnson Rice reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, October 21st. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, October 21st. Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating on the stock. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Finally, Piper Sandler assumed coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target for the company.

View Our Latest Stock Report on AGMB

AgomAb Therapeutics Stock Down 3.2%

AgomAb Therapeutics stock opened at $5.44 on Thursday. AgomAb Therapeutics has a one year low of $5.39 and a one year high of $17.82. The business has a fifty day moving average price of $8.70 and a 200-day moving average price of $11.57.

Insider Buying and Selling

In other news, CFO Pierre Kemula acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were purchased at an average price of $8.59 per share, for a total transaction of $85,900.00. Following the completion of the transaction, the chief financial officer owned 10,000 shares of the company’s stock, valued at $85,900. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Epstein purchased 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was acquired at an average cost of $6.90 per share, with a total value of $103,500.00. Following the purchase, the director directly owned 40,000 shares of the company’s stock, valued at $276,000. This trade represents a 60.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 75,980 shares of company stock valued at $577,112 over the last three months.

About AgomAb Therapeutics

(Get Free Report)

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.

Further Reading

Analyst Recommendations for AgomAb Therapeutics (NASDAQ:AGMB)

Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.